CRISPR Therapeutics and ProBioGen sign collaboration and license agreement
CRISPR Therapeutics announced a multi-year research collaboration focused on the development of novel in vivo delivery modalities for CRISPR/Cas9 leveraging ProBioGen’s existing technology and expertise. Technical and financial details of the collaboration were not disclosed. January 22, 2019